Race Oncology accelerates gamechanging cancer drug

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Dr Smith told HotCopper about “reformulating” old drugs to put together their RC220 design and how they’ve confirmed recent improving effects.

He also spoke on why working on from an old drug means Race will be “unlikely to face many of the hurdles companies face in terms of the drug working and [safety questions] that often lead to some very expensive studies.”

“We’re excited about unveiling everything as we roll forward,” he added.

Join the discussion: See what HotCopper users are saying about Actinogen Medical Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.